Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Sarcoma 1Other solid neoplasm 1Gynecologic 1Gastrointestinal 1

Conditions

Ovarian Neoplasms 2Colorectal Neoplasms 2Uterine Neoplasms 1Uterine Cervical Neoplasms 1Small Cell Lung Carcinoma 1Sarcoma 1Neoplasms 1Neoplasm Metastasis 1Mesothelioma 1Kidney Neoplasms 1Head and Neck Neoplasms 1Gastrointestinal Stromal Tumors 1Carcinoma, Non-Small-Cell Lung 1

Interventions

tislelizumab 2tazemetostat 2belinostat 2spartalizumab 1pembrolizumab 1fludarabine phosphate 1fludarabine 1Temozolomide 1Sorafenib 1Rifampin 1Quality of Life 1Plicamycin 1Pemetrexed 1Patient Reported Outcome Measures 1PM 01183 1OSI 930 1Nivolumab 1Molecular Diagnostic Techniques 1LY2940680 1Itraconazole 1Irinotecan 1Immunotherapy, Adoptive 1Immunotherapy 1Imatinib Mesylate 1Fluorouracil 1Fluorodeoxyglucose F18 1Erlotinib Hydrochloride 1Drug Therapy 1Doxepin 1Cyclophosphamide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Mesothelioma × OSI 930 × Sarcoma × Clear all
NCT00603356 2011-09-27

Phase I Study of OSI-930 and Erlotinib in Cancer Tumors

Astellas Pharma Inc

Phase 1 Completed
60 enrolled
GastrointestinalGynecologicOther solid neoplasmSarcomaThoracic

Mesothelioma, Neoplasms, Ovarian Neoplasms, Sarcoma, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡